The estimated Net Worth of Teena Lerner is at least $537 mil dollars as of 6 February 2020. Teena Lerner owns over 30,423 units of Applied Therapeutics stock worth over $258,380 and over the last 6 years he sold APLT stock worth over $0. In addition, he makes $278,581 as Lead Independent Director at Applied Therapeutics.
Sign up
Teena Lerner APLT stock SEC Form 4 insiders trading
Teena has made over 1 trades of the Applied Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 30,423 units of APLT stock worth $74,841 on 6 February 2020.
The largest trade he's ever made was exercising 30,423 units of Applied Therapeutics stock on 6 February 2020 worth over $74,841. On average, Teena trades about 3,380 units every 0 days since 2019. As of 6 February 2020 he still owns at least 49,593 units of Applied Therapeutics stock.
You can see the complete history of Teena Lerner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Teena Lerner biography
Dr. Teena L. Lerner Ph.D. serves as Lead Independent Director of the Company. Dr. Lerner is an expert in healthcare investing, with over over 20 years of in-depth experience in the areas of healthcare evaluation, investment research, finance and accounting. Dr. Lerner was the Founder and CEO of Rx Capital Management, a long-short healthcare equity hedge fund. Previously she was a Principal at Pequot Capital Management and a Managing Director in Equity Research at Lehman Brothers. At Rx Capital and Pequot Capital, Dr. Lerner managed investment funds of $700 million and $1.5 billion, respectively. While at Lehman Brothers, Dr Lerner achieved Institutional Investor Magazine “All Star” designation in biotechnology for 7 consecutive years. Dr. Lerner currently serves on the Board the Technology Transfer Advisory Committee of The Rockefeller University, where she earned her PhD. Dr. Lerner holds an MBA in Finance from New York University, a PhD in Molecular Biology from Rockefeller University, and a CFA charter from the Institute of Chartered Financial Analysts.
What is the salary of Teena Lerner?
As the Lead Independent Director of Applied Therapeutics, the total compensation of Teena Lerner at Applied Therapeutics is $278,581. There are 7 executives at Applied Therapeutics getting paid more, with shoshana Shendelman having the highest compensation of $11,590,000.
How old is Teena Lerner?
Teena Lerner is 62, he's been the Lead Independent Director of Applied Therapeutics since 2017. There are 2 older and 8 younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics, Inc. is Jay Skyler, 73, who is the Independent Director.
What's Teena Lerner's mailing address?
Teena's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Insiders trading at Applied Therapeutics
Over the last 6 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus, eShoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
What does Applied Therapeutics do?
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
What does Applied Therapeutics's logo look like?
Complete history of Teena Lerner stock trades at Applied Therapeutics
Applied Therapeutics executives and stock owners
Applied Therapeutics executives and other stock owners filed with the SEC include:
-
shoshana Shendelman,
Chairman of the Board, President, Chief Executive Officer, Founder -
Riccardo Perfetti,
Chief Medical Officer -
Mark Vignola,
Chief Financial Officer -
Dr. Shoshana Shendelman Ph.D.,
Chair of the Board of Directors, Founder, Pres, CEO & Sec. -
Dr. Riccardo Perfetti,
Chief Medical Officer -
Leslie Funtleyder,
Independent Director -
Dr. Charles Silberstein M.D., CFA,
CFO & Head of Bus. Devel. -
Teena Lerner,
Lead Independent Director -
Joel Marcus,
Independent Director -
Stacy Kanter,
Independent Director -
Jay Skyler,
Independent Director -
Maeve Conneighton,
IR Contact Officer -
Adam Hansard,
Chief Commercial Officer -
Chids Mahadevan,
VP of Fin. & Chief Accounting Officer -
Real Estate Equities, Inc.A...,
-
Constantine Chinoporos,
See Remarks -
Charles Silberstein,
Chief Financial Officer -
Adam Hansard,
Chief Commercial Officer -
Corwin Dale Hooks,
Chief Commercial Officer -
Steven A. Ortega,
Principal Accounting Officer -
Chids Mahadevan,
See Remarks